Clinical and genetic characteristics predict outcomes of acute myeloid leukemia patients with FLT3 mutations receiving venetoclax‐based therapy

作者：Guangyang Weng, Jingya Huang, Na An, Yu Zhang, Guopan Yu, Zhiqiang Sun, Dongjun Lin, Lan Deng, Xinquan Liang, Jie Xiao, Hongyu Zhang, Ziwen Guo, Xin He, Hua Jin, Qifa Liu, Xin Du · 发表于：Cancer Medicine · 年份：2024 · DOI：10.1002/cam4.6885 · 被引用次数：3 · 研究领域：Acute Myeloid Leukemia Research、Hematopoietic Stem Cell Transplantation、Histone Deacetylase Inhibitors Research

Abstract Background Acute myeloid leukemia (AML) is a heterogeneous disease, and its heterogeneity is associated with treatment response. Despite the demonstrated success of venetoclax (VEN)‐based therapy for AML, the effect of FLT3 mutations on the efficacy of the therapy is poorly understood. We aimed to compare the efficacy of VEN‐based therapy between FLT3‐mutated (FLT3 mut ) and FLT3 wild‐type (FLT3 wt ) patients and identify the predictors of efficacy in FLT3 mut patients. Methods A total of 266 AML patients (127 newly diagnosed [ND] and 139 refractory/relapsed [R/R]) receiving VEN‐based regimens were enrolled in this study. A retrospective analysis was performed, and the treatment responses and overall survival (OS) of FLT3 mut and FLT3 wt patients were compared. Logistic regression and Cox proportional hazards model were applied to examine the clinical and genetic predictors of outcomes. Results With a median of two cycles of VEN‐based therapy, for the ND AML cohort, the FLT3 mut group had a comparable composite complete remission (CRc) rate with the FLT3 wt group (79.3% vs. 61.2%, p = 0.072). For the R/R AML cohort, the FLT3 mut group exhibited a lower CRc rate than the FLT3 wt group. With a median follow‐up of 8.6 months (95% confidence interval [CI], 8.0–10), the median OS observed in the FLT3 mut and FLT3 wt groups for both cohorts were close (14.0 vs. 19.9 months, p = 0.356; 10.0 vs. 11.9 months, p = 0.680). For the ND AML cohort, in FLT3 mut patients, MRD‐positi...